Brief: Coya Therapeutics Announces Publication Of Potential Novel Blood Biomarker Data In Amyotrophic Lateral Sclerosis (Als) Patients
31/08/2023 13:38
Aug 31 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS ANNOUNCES PUBLICATION OF POTENTIAL NOVEL
BLOOD
BIOMARKER DATA IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS
THAT ACCURATELY REFLECT THERAPEUTIC RESPONSES WHEN TREATED WITH
REGULATORY T CELL (TREG) ENHANCING THERAPIES
Source text for Eikon: ID:nBw6Z49M8a
Further company coverage: COYA.O
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)